Results 31 to 40 of about 1,013 (109)

Lorlatinib Tolerability and Association With Clinical Outcomes in Patients With Advanced ALK- or ROS1-Rearranged NSCLC: A Brief Report

JTO Clinical and Research Reports, 2023
Introduction: Treatment with lorlatinib for patients with advanced ALK- and ROS1-rearranged NSCLC (ALK+ and ROS1+ NSCLC) is associated with a unique set of adverse events (AEs) often requiring dose reduction.
Rohit Thummalapalli, MD, Noura J. Choudhury, MD, Fiona Ehrich, MS, Tyler Beardslee, PharmD, Danielle Brazel, MD, Shannon S. Zhang, MD, Shelby Merchant, PharmD, Monica F. Chen, MD, Glenn Heller, PhD, Suresh S. Ramalingam, MD, Sai-Hong Ignatius Ou, MD, PhD, Kathryn F. Mileham, MD, Gregory J. Riely, MD, PhD   +12 more
doaj   +1 more source

Circulating tumor DNA reveals mechanisms of lorlatinib resistance in patients with relapsed/refractory ALK-driven neuroblastoma

, 2023
This repository contains structural and ordinary differential equations (ODE) files used to model resistance to lorlatinib in anaplastic lymphoma kinase (ALK) with secondary mutations.
Smita Matkar, Esther R. Berko, Zaritza O. Petrova, Gabriela M. Witek   +3 more
core   +1 more source

Lorlatinib-Related Vision Loss: Two Cases of Non-Small Cell Lung Cancer with Blindness

, 2023
Data on the management of Grade 3-4 visual disorders due to lorlatinib remain limited. We presented two cases of Grade-4 vision loss due to lorlatinib. We interrupted lorlatinib and initiated a pulse steroid in these patients.
Karadağ, İbrahim, Işik, Şeyma, Yildirim, Özgen Ahmet, Yücel, ŞEBNEM, Karakaya, Serdar   +4 more
core   +1 more source

Diverse Resistance Mechanisms to the Third-Generation ALK Inhibitor Lorlatinib in ALK-Rearranged Lung Cancer

, 2020
International audiencePurpose: Lorlatinib is a third-generation anaplastic lymphoma kinase (ALK) tyrosine kinase inhibitor with proven efficacy in patients with ALK-rearranged lung cancer previously treated with first- and second-generation ALK ...
Rizvi, Ahsan, Frias, Rosa, Olaussen, Ken, Bahleda, Rastilav, Hollebecque, Antoine, Lavaud, Pernelle, Facchinetti, Francesco, Deas, Olivier, Gazzah, Anas, Nicotra, Claudio, Angevin, Eric, Mahjoubi, Linda, Tesson, Pauline, Abou Lovergne, Aurélie, Mezquita, Laura, Auger, Nathalie, Recondo, Gonzalo, Besse, Benjamin, Michiels, Stefan, Friboulet, Luc, Lacroix, Ludovic, Scoazec, Jean-Yves, Tselikas, Lambros, Eggermont, Alexander, Howarth, Karen, Soria, Jean-Charles, Sourisseau, Tony, Braye, Floriane, Ngo-Camus, Maud, de Baere, Thierry, Galissant, Justine, Solary, Eric, Planchard, David, Richon, Catherine, Thiery, Jean Paul, Andre, Fabrice, Massard, Christophe, Bigot, Ludovic, Samofalova, Dariia, Vassal, Gilles, Naltet, Charles   +40 more
core   +1 more source

Monitoring and Managing Lorlatinib Adverse Events in the Portuguese Clinical Setting:A Position Paper

, 2021
Rearrangements in the anaplastic lymphoma kinase (ALK) and proto-oncogene tyrosine-protein kinase ROS (ROS1) genes characterise two distinct molecular subsets of non-small cell lung cancer (NSCLC) tumours.
Aguiar, Carlos, Marques, José Bravo, Barata, Fernando, Hespanhol, Venceslau, Marques, Tiago Reis   +4 more
core   +1 more source

Lorlatinib for advanced ROS1+ non-small-cell lung cancer: results of the IFCT-1803 LORLATU study

, 2022
INTRODUCTION: ROS1-rearranged (ROS1+) non-small-cell lung cancer (NSCLC) is a rare lung cancer with limited treatment options. Phase I-II studies with ROS1-tyrosine kinase inhibitors (TKIs) included small numbers of patients and real-world data are ...
Avrillon, V., Lamy, R., Roch, Benoît, Westeel, V., Otto, Josiane, Ricordel, C., Tillon-Strozyk, J., Bennouna, Jaafar, Zalcman, G., Lamy, Régine, Galland-Girodet, S., Bouledrak, Karima, Duruisseaux, Michaël, Roch, B., Cadranel, J., Moro-Sibilot, Denis L., Besse, Benjamin, Bouledrak, K., Egenod, T., Westeel, Virginie, Baldacci, S., Zalcman, Gérard, Cadranel, Jacques L., Odier, Luc, Prevost, A., Moro-Sibilot, D., Odier, L., Galland-Girodet, Sigolène, Coudurier, M., Girard, Nicolas, Girard, N., Duruisseaux, M., Coudurier, Marie, Otto, J., Besse, B., Bennouna, J., Baldacci, Simon, Egenod, Thomas, Missy, P., Ricordel, Charles, Avrillon, Virginie, Missy, Pascale   +41 more
core   +1 more source

Cost-Effectiveness of Lorlatinib for the Treatment of Adult Patients with Anaplastic Lymphoma Kinase Positive Advanced Non-Small Cell Lung Cancer in Spain

, 2023
María Presa,1 David Vicente,2 Antonio Calles,3 Laura Salinas-Ortega,1 Jaesh Naik,4 Luis F García,5 Javier Soto6 1Health Economics, Pharmacoeconomics and Outcomes Research Iberia (PORIB), Madrid, Spain; 2Medical Oncology Department, Hospital Universitario
García LF, Presa M, Vicente D, Salinas-Ortega L, Calles A, Soto J, Naik J   +6 more
core  

A user\u27s guide to lorlatinib

, 2020
Rearrangements of the ALK gene are found in approximately 5% of non-small-cell lung cancer. It is of particular importance to test for this rearrangement in patients with metastatic lung adenocarcinoma because these tumors are highly sensitive to therapy
Sukari, Ammar, Ge, Yubin, Ou, Sai-Hong Ignatius, Nagasaka, Misako, Kukreja, Geetika   +4 more
core   +1 more source

Regulatory harmonization: Evolution, globalization and future directions

British Journal of Clinical Pharmacology, EarlyView.
Regulatory harmonization has become an increasingly important and accepted approach to streamline regulatory review processes and expedite access to safe, effective and high‐quality medicines globally. This review explores the evolution and current status of regulatory harmonization, convergence and reliance initiatives.
Orin Chisholm, Elaine Y. L. Blair, Christine Y. Lu   +2 more
wiley   +1 more source

Efficacy of lorlatinib in the treatment of ALK-positive non-small cell lung cancer patients with progression on crizotinib: personal experience

Медицинский совет, 2021
Introduction. Lorlatinib is a  third generation ALK tyrosine kinase inhibitor. Back in  2018, the  drug underwent accelerated FDA approval and was recommended for the treatment of patients with ALK-positive non-small cell lung cancer after progression on
K. K. Laktionov, E. V. Reutova, S. Yu. Kruteleva, E. Yu. Antonova   +3 more
doaj   +1 more source